William Creasman to Drug Evaluation
This is a "connection" page, showing publications William Creasman has written about Drug Evaluation.
Connection Strength
0.116
-
Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001 Jul; 82(1):7-10.
Score: 0.048
-
A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989 Oct; 7(10):1462-8.
Score: 0.021
-
Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Gynecol Oncol. 1986 Jan; 23(1):101-4.
Score: 0.016
-
A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1984 Jun; 7(3):257-60.
Score: 0.015
-
Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Apr; 33(1):68-70.
Score: 0.005
-
Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1984 May; 68(5):809-11.
Score: 0.004
-
Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. Am J Clin Oncol. 1983 Jun; 6(3):273-5.
Score: 0.003
-
Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2089-92.
Score: 0.003